Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.

Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP.

Pharmacol Rev. 2019 Apr;71(2):198-224. doi: 10.1124/pr.118.015768. Review.

PMID:
30890566
2.

The PEARRL reviews - innovative drug development strategies tailored to facilitate earlier access to new oral medicines.

Griffin BT, Dressman JB.

J Pharm Pharmacol. 2019 Apr;71(4):439-440. doi: 10.1111/jphp.13083. No abstract available.

PMID:
30828829
3.

New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.

Koehl NJ, Holm R, Kuentz M, Griffin BT.

Pharm Res. 2019 Feb 22;36(4):56. doi: 10.1007/s11095-019-2590-y.

PMID:
30796596
4.

A Dairy-Derived Ghrelinergic Hydrolysate Modulates Food Intake In Vivo.

Howick K, Wallace-Fitzsimons SE, Kandil D, Chruścicka B, Calis M, Murphy E, Murray BA, Fernandez A, Barry KM, Kelly PM, Ryan AM, Cryan JF, Griffin BT, Schellekens H.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2780. doi: 10.3390/ijms19092780.

5.

Regulation of biosimilar medicines and current perspectives on interchangeability and policy.

O'Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT.

Eur J Clin Pharmacol. 2019 Jan;75(1):1-11. doi: 10.1007/s00228-018-2542-1. Epub 2018 Sep 5. Review.

PMID:
30187103
6.

Food for thought: formulating away the food effect - a PEARRL review.

O'Shea JP, Holm R, O'Driscoll CM, Griffin BT.

J Pharm Pharmacol. 2019 Apr;71(4):510-535. doi: 10.1111/jphp.12957. Epub 2018 Jun 28. Review.

PMID:
29956330
7.

Drug-gut microbiota interactions: implications for neuropharmacology.

Walsh J, Griffin BT, Clarke G, Hyland NP.

Br J Pharmacol. 2018 Dec;175(24):4415-4429. doi: 10.1111/bph.14366. Epub 2018 Jun 28. Review.

PMID:
29782640
8.

Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.

O'Callaghan J, Griffin BT, Morris JM, Bermingham M.

BioDrugs. 2018 Jun;32(3):267-280. doi: 10.1007/s40259-018-0281-6.

9.

Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism.

Enright EF, Griffin BT, Gahan CGM, Joyce SA.

Pharmacol Res. 2018 Jul;133:170-186. doi: 10.1016/j.phrs.2018.04.009. Epub 2018 Apr 13. Review.

PMID:
29660405
10.

The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review.

Henze LJ, Koehl NJ, O'Shea JP, Kostewicz ES, Holm R, Griffin BT.

J Pharm Pharmacol. 2019 Apr;71(4):581-602. doi: 10.1111/jphp.12912. Epub 2018 Apr 10. Review.

PMID:
29635685
11.

Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide.

Henze LJ, Griffin BT, Christiansen M, Bundgaard C, Langguth P, Holm R.

Eur J Pharm Sci. 2018 Jun 15;118:183-190. doi: 10.1016/j.ejps.2018.03.017. Epub 2018 Mar 17.

PMID:
29559403
12.

Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate.

Donovan MD, Abduljalil K, Cryan JF, Boylan GB, Griffin BT.

Biopharm Drug Dispos. 2018 Mar;39(3):125-134. doi: 10.1002/bdd.2119. Epub 2018 Feb 22.

PMID:
29319897
13.

Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization.

Howick K, Alam R, Chruscicka B, Kandil D, Fitzpatrick D, Ryan AM, Cryan JF, Schellekens H, Griffin BT.

Int J Pharm. 2018 Jan 30;536(1):63-72. doi: 10.1016/j.ijpharm.2017.11.051. Epub 2017 Nov 23.

PMID:
29175643
14.

Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.

O'Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, Griffin BT.

Regul Toxicol Pharmacol. 2017 Aug;88:252-261. doi: 10.1016/j.yrtph.2017.06.013. Epub 2017 Jun 27.

15.

Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.

O'Shea JP, Nagarsekar K, Wieber A, Witt V, Herbert E, O'Driscoll CM, Saal C, Lubda D, Griffin BT, Dressman JB.

J Pharm Pharmacol. 2017 Oct;69(10):1284-1292. doi: 10.1111/jphp.12767. Epub 2017 Jun 20.

PMID:
28631822
16.

Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.

Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, Daly L, MacEneaney P, O' Sullivan K, Prado CM, Ryan AM.

Clin Nutr ESPEN. 2016 Jun;13:e39-e45. doi: 10.1016/j.clnesp.2016.04.001. Epub 2016 May 6.

PMID:
28531567
17.

Impact of Gut Microbiota-Mediated Bile Acid Metabolism on the Solubilization Capacity of Bile Salt Micelles and Drug Solubility.

Enright EF, Joyce SA, Gahan CG, Griffin BT.

Mol Pharm. 2017 Apr 3;14(4):1251-1263. doi: 10.1021/acs.molpharmaceut.6b01155. Epub 2017 Feb 24.

PMID:
28186768
18.

From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.

Howick K, Griffin BT, Cryan JF, Schellekens H.

Int J Mol Sci. 2017 Jan 27;18(2). pii: E273. doi: 10.3390/ijms18020273. Review.

19.

In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.

McCarthy CA, Faisal W, O'Shea JP, Murphy C, Ahern RJ, Ryan KB, Griffin BT, Crean AM.

J Control Release. 2017 Mar 28;250:86-95. doi: 10.1016/j.jconrel.2016.12.043. Epub 2017 Jan 27.

PMID:
28132935
20.

The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.

Enright EF, Gahan CG, Joyce SA, Griffin BT.

Yale J Biol Med. 2016 Sep 30;89(3):375-382. eCollection 2016 Sep. Review.

21.

Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo.

Evans JC, Malhotra M, Guo J, O'Shea JP, Hanrahan K, O'Neill A, Landry WD, Griffin BT, Darcy R, Watson RW, O'Driscoll CM.

Nanomedicine. 2016 Nov;12(8):2341-2351. doi: 10.1016/j.nano.2016.06.014. Epub 2016 Jul 4.

PMID:
27389146
22.

Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs.

Griffin BT, Guo J, Presas E, Donovan MD, Alonso MJ, O'Driscoll CM.

Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):367-380. doi: 10.1016/j.addr.2016.06.006. Epub 2016 Jun 16. Review.

PMID:
27320644
23.

Lipid-based nanocarriers for oral peptide delivery.

Niu Z, Conejos-Sánchez I, Griffin BT, O'Driscoll CM, Alonso MJ.

Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):337-354. doi: 10.1016/j.addr.2016.04.001. Epub 2016 Apr 11. Review.

PMID:
27080735
24.

Chronic P-glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression.

O'Brien FE, Moloney GM, Scott KA, O'Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF.

Pharmacol Res Perspect. 2015 Oct 26;3(6):e00190. doi: 10.1002/prp2.190. eCollection 2015 Dec.

25.

Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives.

Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB.

Drugs. 2016 Apr;76(6):647-61. doi: 10.1007/s40265-016-0554-7. Review.

PMID:
26943929
26.

In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide.

Donovan MD, Schellekens H, Boylan GB, Cryan JF, Griffin BT.

Eur J Pharmacol. 2016 Jan 5;770:117-25. doi: 10.1016/j.ejphar.2015.12.001. Epub 2015 Dec 8.

PMID:
26673740
27.

Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Donovan MD, Boylan GB, Murray DM, Cryan JF, Griffin BT.

Br J Clin Pharmacol. 2016 Jan;81(1):62-77. doi: 10.1111/bcp.12753. Epub 2015 Nov 4. Review.

28.

Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.

O'Shea JP, Faisal W, Ruane-O'Hora T, Devine KJ, Kostewicz ES, O'Driscoll CM, Griffin BT.

Eur J Pharm Biopharm. 2015 Oct;96:207-16. doi: 10.1016/j.ejpb.2015.07.014. Epub 2015 Jul 26.

PMID:
26215636
29.

Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres.

Keohane K, Rosa M, Coulter IS, Griffin BT.

Drug Dev Ind Pharm. 2016;42(2):245-53. doi: 10.3109/03639045.2015.1044905. Epub 2015 Jun 17.

PMID:
26083078
30.

The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat.

Donovan MD, O'Brien FE, Boylan GB, Cryan JF, Griffin BT.

J Pharm Pharmacol. 2015 Apr;67(4):501-10. doi: 10.1111/jphp.12341. Epub 2014 Dec 10.

PMID:
25490899
31.

Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies.

Lawless E, Griffin BT, O'Mahony A, O'Driscoll CM.

Pharm Res. 2015 May;32(5):1817-29. doi: 10.1007/s11095-014-1578-x. Epub 2014 Nov 27.

PMID:
25428258
32.

PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability.

Godinho BM, Ogier JR, Quinlan A, Darcy R, Griffin BT, Cryan JF, O'Driscoll CM.

Int J Pharm. 2014 Oct 1;473(1-2):105-12. doi: 10.1016/j.ijpharm.2014.06.054. Epub 2014 Jun 30.

PMID:
24992319
33.

Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.

Stillhart C, Imanidis G, Griffin BT, Kuentz M.

Pharm Res. 2014 Dec;31(12):3426-44. doi: 10.1007/s11095-014-1432-1. Epub 2014 Jun 25.

PMID:
24962509
34.

Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles.

Keohane K, Brennan D, Galvin P, Griffin BT.

Int J Pharm. 2014 Jun 5;467(1-2):60-9. doi: 10.1016/j.ijpharm.2014.03.051. Epub 2014 Mar 28.

PMID:
24680950
35.

The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.

O'Brien FE, O'Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF.

Behav Brain Res. 2014 Mar 15;261:17-25. doi: 10.1016/j.bbr.2013.11.027. Epub 2013 Nov 23.

PMID:
24280122
36.

Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.

Griffin BT, Kuentz M, Vertzoni M, Kostewicz ES, Fei Y, Faisal W, Stillhart C, O'Driscoll CM, Reppas C, Dressman JB.

Eur J Pharm Biopharm. 2014 Apr;86(3):427-37. doi: 10.1016/j.ejpb.2013.10.016. Epub 2013 Oct 31.

PMID:
24184675
37.

Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.

O'Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2259-72. doi: 10.1017/S1461145713000692. Epub 2013 Aug 9.

PMID:
23931269
38.

A novel lipid-based solid dispersion for enhancing oral bioavailability of Lycopene--in vivo evaluation using a pig model.

Faisal W, Ruane-O'Hora T, O'Driscoll CM, Griffin BT.

Int J Pharm. 2013 Sep 10;453(2):307-14. doi: 10.1016/j.ijpharm.2013.06.027. Epub 2013 Jun 21.

PMID:
23796833
39.

P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

O'Brien FE, O'Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF.

Neuropsychopharmacology. 2013 Oct;38(11):2209-19. doi: 10.1038/npp.2013.120. Epub 2013 May 14.

40.
41.

Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.

O'Brien FE, Clarke G, Fitzgerald P, Dinan TG, Griffin BT, Cryan JF.

Br J Pharmacol. 2012 Jun;166(4):1333-43. doi: 10.1111/j.1476-5381.2012.01858.x.

42.

Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

O'Brien FE, Dinan TG, Griffin BT, Cryan JF.

Br J Pharmacol. 2012 Jan;165(2):289-312. doi: 10.1111/j.1476-5381.2011.01557.x. Review.

43.

Efficacy of a Lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes.

Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG.

Bioeng Bugs. 2010 Jan-Feb;1(1):66-74. doi: 10.4161/bbug.1.1.10284.

44.

Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors.

Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG.

J Med Microbiol. 2010 Aug;59(Pt 8):904-12. doi: 10.1099/jmm.0.018770-0. Epub 2010 May 20.

PMID:
20488938
45.

Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport.

Faisal W, O'Driscoll CM, Griffin BT.

J Pharm Pharmacol. 2010 Mar;62(3):323-31. doi: 10.1211/jpp.62.03.0006.

PMID:
20487215
46.

Lactococcus lactis as a cell factory for delivery of therapeutic proteins.

Bahey-El-Din M, Gahan CG, Griffin BT.

Curr Gene Ther. 2010 Feb;10(1):34-45. Review.

PMID:
20156189
47.

Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model.

Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG.

Vaccine. 2008 Sep 26;26(41):5304-14. doi: 10.1016/j.vaccine.2008.07.047. Epub 2008 Aug 6.

PMID:
18691625
48.

Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000.

Bahey-El-Din M, Griffin BT, Gahan CG.

Microb Cell Fact. 2008 Jul 29;7:24. doi: 10.1186/1475-2859-7-24.

49.

Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.

O'Driscoll CM, Griffin BT.

Adv Drug Deliv Rev. 2008 Mar 17;60(6):617-24. Epub 2007 Nov 6.

PMID:
18155800
50.

Supplemental Content

Loading ...
Support Center